Preclinical studies have demonstrated that injecting recombinant HMGB1 (rHMGB1) into the lateral ventricles of neonatal mice can induce depression-like behaviors, while anti-HMGB1 antibody treatment suppresses microglial activation and ameliorate these behaviors (17). Here, HMGB1 is linked to depressive symptom measurement.